Please assess the completion status of the following clinical trial:

Trial Title: Neurobiological Basis of Response to Guanfacine Extended Release in Children and Adolescents With ADHD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of any subtype of ADHD~* Normal findings on physical exam, laboratory studies, vital signs, and ECG~* Weight = 60 kgs or less~* Able to complete study procedures and swallow capsules;~* Willing to commit to the entire visit schedule~* Off treatment or have been discontinued from their previous medication for two weeks.~Exclusion Criteria:~* Psychiatric comorbidity except Oppositional Defiant Disorder \[ODD\], Simple Phobia, and dysthymia (unless ongoing medication treatment is required);~* Currently a suicide risk, has previously made a suicide attempt or has a prior history of suicidal behavior;~* Has failed treatment with an adequate trial of an alpha-2 adrenergic agonist;~* Known or suspected allergy, hypersensitivity, or clinically significant intolerance to guanfacine hydrochloride.~Children may not:~* be treated with systemic medication for a medical or psychiatric illness that have CNS effects or affect cognitive function;~* have a known history or presence of structural cardiac abnormalities, exercise-related cardiac events, or clinically significant bradycardia;~* have orthostatic hypotension or a known history of hypertension;~* have an abnormal ECG that is deemed clinically significant;~* have a history of alcohol or other substance abuse or dependence within the last 6 months;~* use any medications that affect BP or heart rate (excluding the subject's current ADHD medication at screening);~* use another investigational medicinal product or participation in a clinical study within 30 days prior to the baseline visit;~* be significantly overweight based on Center for Disease Control and Prevention Body Mass Index (BMI)-for-age gender specific charts;~* have body weight of less than 25kg;~* have a clinically important abnormality on urine drug and alcohol screen (excluding the subject's current ADHD stimulant, if applicable);~* be female and currently pregnant or lactating;~* have symptoms indicative of a primary sleep disorder.~* have braces or other metal permanently placed within their body.~* be too anxious to tolerate the fMRI procedure, or be claustrophobic.

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- guanfacine hydrochloride XR (Type: EXPERIMENTAL): Flexible dose titration of guanfacine extended release (Intuniv; active medication). The medication is titrated in doses from 1 - 4 mg once daily
- Placebo Group (Type: PLACEBO_COMPARATOR): Flexible dose titration of placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).